Mikhail Blagosklonny is currently professor of Oncology at the Roswell Park Cancer Institute. He was appointed to this position since 15th April 2009. Prior to this coveted appointed he was a Senior Scientist at the Ordway Research Institute in Albany, New York.
Shortly before he took up this job in the year 2002, he was appointed Associate Professor of Medicine at New York Medical College situated at Valhalla in New York.He is an Editor-in Chief of Oncotarget. He also seats in the journal’s Editorial Board of Cell Death and Differentiation.
He is also an Associate Editor of Cancer Biology and Therapy of the same journal. He doubles up as the Founder Editor and Editor in Chief of Cell Cycle journal.Mikhail Blagosklonny is an alumnus of First Pavlov State Medical University of St Petersburg. He graduated with an M.D. in Internal Medicine and a PhD in Experimental Medicine and Cardiology. He is well known for his role in TOR signalling in aging and cancer.
View Mikhail’s profile in LinkedIn
He is even more renowned for his advocacy of the use of the cancer drug Rapamycin for possible longevity of life. He has done a lot of research on cancer and target cancer therapies. He has done research on Biogerontology (Mechanisms of Aging) and has proposed Rapamycin as an anti-aging drug.
He holds many publications under his name. He has published more than 270 papers. He is recorded as having used more than 25,000 citations. He thus holds an h-index of 83.From the foregoing, it is clear that Mikhail Blagosklonny is an accomplished Physician, Scientist and Professor of Medicine and Oncology.
He has risen through the ranks with various top-notch appointments. He now holds the position of Professor of Oncology at the Roswell Park Cancer Institute. He continues to write more publications having written more than 270 paper hitherto. He is passionate in Bio gerontology and has even proposed use of Rapamycin to elongate life.
Follow Mikhail on Loop
Introduction and Stem Cell Basics
Steam Cells have been touted as treatment for lung disease. More specifically…Chronic Obstructive Pulmonary Disease (COPD). Emphysema…Chronic Bronchitis…Pulmonary Fibrosis…and Interstitial Lung Disease. The stem cells are harvested from a patient’s blood and bone marrow. A sample is taken. The stem cells are separated from others. Such as those that might be diseased. The stem cells are then returned to the patient’s bloodstream. The Lung Institute offers advanced stem cell treatment.
Passage and Pulmonary Trap
They re-enter the body through an IV drip. Going to the right side of your heart almost immediately. A heartbeat or two spreads the treatment to your lungs. After this…your blood distributes the item to the rest of your body. Yet when these stem cells start treating the lungs…there is the possibility of a pulmonary trap. This is a double edged sword. As this slows down stem cell treatment for the lungs. But it also slows down further chance of lung disease. More information on lung diseases available at lunginstitute.com.
Blood (Venous) Treatment
Less invasive than bone marrow treatment…this method focuses strictly on blood. This also specializes in hematopoietic stem cells. As opposed to a mixture of hematopoietic and mysenchmal stem cells within bone marrow. Treatment is administered over the course of three days in a clinical outpatient setting. This after a pulmonary function test and prep work are done. Due to this treatment being only blood related…there has ti be more follow up care. Mostly the two week..three month…and six month marks.
Bone Marrow Treatment
This treatment allows patients to breathe easier during their illness. While also requiring a three day process…this outpatient procedure occurs in two parts. Minor surgery is also involved. There are more stem cells within one’s bone marrow. Leading to a higher success rate and a significant improvement on a patient’s quality of life. This method requires additional prep and bloodwork. Along with a pulmonary function test…an electrocardiogram (EKG) is also performed. The fist day of treatment involves a blood sample collected through an IV. Day two is the minor bone marrow surgery. The blood and bone marrow samples are separated and cleaned. Then the clean stem cells are re-introduced through the IV. Follow up treatment begins soon after.
Follow the Lung Institute on Twitter.
Read Testimonials: https://lunginstitute.com/testimonials/